Federal Contractor Profile
Lovelace Biomedical And Environmental Research Institute, INC.
Federal contracting record: $96M obligated across 123 awards from 5 agencies, FY 2016–2025.
Company Profile
UEI (Unique Entity Identifier)
N1UBCLRAPNG6
CAGE Code
2D703
Parent Organization
Lovelace Biomedical Research Institute
Address
2425 RIDGECREST DRIVE, SE, ALBUQUERQUE, NM, 871085129
First Federal Award
Oct 6, 2015
Most Recent Award
Sep 29, 2025
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- $91M
Department of Health and Human Services
95 awards · 95.5% of total
- $4.3M
Department of Defense
23 awards · 4.5% of total
- $0
General Services Administration
3 awards · 0.0% of total
- $0
Department of Homeland Security
1 awards · 0.0% of total
- $0
Department of Veterans Affairs
1 awards · 0.0% of total
Top NAICS Activity
- $39M
541380
TESTING LABORATORIES
7 awards
- $21M
541712
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY)
34 awards
- $18M
541711
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
31 awards
- $12M
541715
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
17 awards
- $4.4M
541714
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
5 awards
- $3.2M
541720
RESEARCH AND DEVELOPMENT IN THE SOCIAL SCIENCES AND HUMANITIES
4 awards
- $976K
541990
ALL OTHER PROFESSIONAL, SCIENTIFIC, AND TECHNICAL SERVICES
4 awards
- $911K
511210
SOFTWARE PUBLISHERS
3 awards
- $1K
541690
OTHER SCIENTIFIC AND TECHNICAL CONSULTING SERVICES
1 awards
- $0
621511
MEDICAL LABORATORIES
1 awards
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Aug 3, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | SUPPORT NON-CLINICAL IMMUNOGENICITY STUDIES OF SARS-COV-2 MICRONEEDLE PATCH VACCINES CANDIDATES IN A SMALL-ANIMAL MODEL | $461K |
| Mar 8, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | SUPPORT NON-CLINICAL IMMUNOGENICITY STUDIES OF SARS-COV-2 MICRONEEDLE PATCH VACCINES CANDIDATES IN A SMALL-ANIMAL MODEL | $295K |
| Dec 16, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 541714 | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | $60K |
| Dec 3, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $180K |
| Nov 15, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $255K |
| Sep 28, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. | $624K |
| Sep 24, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | $584K |
| Sep 24, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $282K |
| Sep 8, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $63K |
| Sep 7, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $595K |
| Sep 3, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 541714 | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER) | $1.6M |
| Aug 30, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $269K |
| Aug 27, 2021 | Department of DefenseFA8052 773 ESS | 541712 | IGF::OT::IGF OMNIBUS III / O3-127AF PAIN MANAGEMENT PROGRAM MANAGEMENT SUPPORT | $270K |
| Aug 19, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 541714 | GENE THERAPY RESEARCH PROGRAM (GTRP) - PHARMACOLOGY/TOXICOLOGY CORE LABORATORY: TASK AREA D - RSA NO. 2041 | $71K |
| Jul 15, 2021 | Department of Health and Human ServicesFDA OFFICE OF ACQ GRANT SVCS | 541720 | IGF::OT::IGF: INVESTIGATE SUBJECTIVE EFFECTS AND NICOTINE PHARMACOKINETICS OF MENTHOLATED SMOKELESS TOBACCO PRODUCTS IN CURRENT USERS | $22K |
| Jun 1, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541711 | PRE-CLINICAL MODELS OF INFECTIOUS DISEASES TASK ORDER B07 | $340K |
| May 25, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $224K |
| Apr 6, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | THE PURPOSE OF THIS TASK ORDER IS THE DEVELOPMENT AND DELIVERY OF A QUALITY ASSURANCE/QUALITY CONTROL (QA/QC) PLAN AND PARTICIPATION IN THE TASK ORDER INITIATION MEETING. | $19K |
| Mar 1, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | $415K |
| Jan 15, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | $102K |
| Dec 3, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NHLBI | 541714 | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | $397K |
| Oct 30, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | $32K |
| Oct 13, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 541715 | THE PURPOSE OF THIS TASK ORDER IS TO FUND THE GUARANTEED MINIMUM AMOUNT OF THE CONTRACT. | $3K |
| Sep 24, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | $1.5M |
| Sep 24, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIDA | 541715 | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | $1.7M |
Related Contractors
Other companies active in NAICS 541380 — TESTING LABORATORIES.
Track Lovelace Biomedical And Environmental Research Institute, INC. Recompetes Before They Post
Mindy monitors Lovelace Biomedical And Environmental Research Institute, INC.'s active contracts and alerts you 12 months before they expire — so you can position to compete on recompete.
Get Free Recompete Alerts